Abstract 18925: The Serum Level of Mir-30a-3p And Mir-31-5p Can Discriminate Responders From Non-responders to CD34 + Cell Therapy in Patients With Dilated Cardiomyopathy
Introduction: The potential predictive value of specific, circulating miRNAs in blood in patiens with non-ischemic dilated cardiomyopathy (DCM) undergoind CD34+ cell therapy remains undefined.
Hypothesis: We assessed the hypothesis that the relative level of specific miRNAs in serum obtained at baseline will discriminate responders from non-responders to stem cell therapy in patients with DCM.
Methods: We enrolled 10 consecutive patients with DCM who underwent transendocardial CD34+ cell transplantation between January and December 2013. All patients received 5-day stimulation with G-CSF; CD34+ cells were selected with apheresis and injected transendocardially guided by electroantomical mapping. Patients were followed for 6 months and good clinical response was defined as an increase of left ventricular ejection fraction (LVEF) ≥5%. Before cell therapy, total RNA was isolated from serum with the miRCURY RNA Isolation Biofluids Kit. cDNA synthesis and real-time qPCR were performed using the miRCURY Locked Nucleic Acid and Universal RT microRNA PCR system with The qPCRs were run on a ViiA7 thermocycler.
Results: At 6 months after therapy, good clinical response was found in 5 patients (Group A), and 5 patients failed to respond to cell therapy (Group B). The two groups did not differ with regards to age (55±9 years in Group A vs. 57±3 years in Group B; P=0.58), male gender (87% vs. 100%; P=0.34), baseline LVEF (33±5% vs. 28±8%; P=0,28), LVEDD (6.6±0.4 cm vs. 6.9±0.7 cm; P=0.33) or NTproBNP levels (1460±932 pg/mL vs. 4540±3808 pg/mL; P=0.15). When analyzing the pool of miRNAs we found the serum level of miR-30a-3p and miR- 31-5p to be significantly different between two study groups (both had adjusted P values of 0.031). The serum level of miR- 31-5p was higher in the group of responders (log2 fold change of 6.78) while the serum level of miR-30a-3p was higher in the group of non-responders (log2 fold change of 4.98).
Conclusions: In patients with DCM undergoing CD34+ cell therapy specific serum miRNAs appear to discriminate clinical responders from non-responders. Therefore, they could be used as a tool when selecting appropriate patients for stem cell therapy.
Author Disclosures: T. Pajic: None. N. Klinec: None. M. Sever: None. P. Cernelc: None. G. Poglajen: None. F. Haddad: None. B. Vrtovec: None.
- © 2015 by American Heart Association, Inc.